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Huntington's Disease Centre, UCL Institute of Neurology, National Hospital for Neurology & Neurosurgery, Queen Square, London, UKMany scientists and people from families affected by Huntington's ural means of regulating post-transcriptional gene expression across
disease prefer to avoid ‘the C-word’: cure. Acknowledging this, I still
feel it is justiﬁable to describe Huntington's as the most curable incur-
able brain disorder.
Everyone with HD has the same basic problem – a CAG expansion
mutation in HTT, encoding a polyglutamine tract in the huntingtin pro-
tein (The Huntington's Disease Collaborative Research Group, 1993).
Everyone with that problem will develop HD at some point, slowly
succumbing to progressive cognitive, motor and psychiatric impair-
ment. It is almost fully penetrant and truly dominant, and the genetic
test is bleakly reliable.
The more prevalent neurodegenerative diseases like Alzheimer's
and Parkinson's lack this certainty: only a tiny minority of cases have a
deﬁned genetic cause. Therapeutic targets must be prosecuted on the
balance of probability. In HD, we operate ‘beyond reasonable doubt’:
mutant huntingtin is a smoking gun. Anything that cannot be connected
to the mutation or protein may conﬁdently be discarded.
History has shown HD is an easy problem to deﬁne, for which it is
surprisingly difﬁcult to ﬁnd solutions. Twenty-two years of research
since the gene discovery in 1993 (see Fig. 1) has revealed much about
huntingtin protein and its toxic twin, resulting in numerous
genetically-accurate cell and animal models and theories of molecular
and cellular pathogenesis – yielding multiple therapeutic targets (Ross
et al., 2014; Wild and Tabrizi, 2014).
Based on our early understanding of its pathogenesis, the HD ﬁeld
tested an array of already-licensed neuroactive drugs (including baclo-
fen, lamotrigine, riluzole and minocycline), plus a whole shelf of
‘nutraceuticals’ held to be generally good for neurons (creatine, coen-
zyme Q, ﬁsh oil and others). Nothing worked (Mestre et al., 2009).
A failed drug does not imply a failed trial. Collectively, these experi-
ences improved the ﬁeld's ability to design and run trials that can give a
deﬁnitive answer, and to prioritise therapeutic targets and generate
comprehensive preclinical data to inform decisions about advancing to
clinical trials.
We also have at our disposal a new generation of drugs that take
aim at the known cause of HD. 2005 saw the ﬁrst attempt to ‘silence’
the HTT gene in an HD mouse model, using RNA interference. Origi-
nally discovered in petunia ﬂowers, and eventually found to be a nat-E-mail address: e.wild@ucl.ac.uk.
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approach involves designing and synthesising an oligonucleotide
molecule with a sequence complementary to the messenger RNA of
the gene of interest. mRNA bound to the drug molecule is degraded
by cellular enzymes, diminishing the manufacture of the target pro-
tein. Conceptually, the technique is as simple as turning off the water
in an overﬂowing bathtub; but that does not mean it is easy to imple-
ment for a neurodegenerative disease – even one with a clear, dom-
inant genetic cause.
The mice whose brains were injected with the RNA interference
compound did not just deteriorate more slowly – their motor problems
improved, and regression of neuropathology was also seen (Harper
et al., 2005). Similar improvements have been seen now with several
such drugs in different model animals. These models may be imperfect
but are the only current means by which preclinical efﬁcacy can be
judged.
Meanwhile, a quiet revolution has been taking place in the ﬁeld of
HD biomarkers. The need for measures that can give an early, objective
indication of progression or therapeutic effect is common to all neuro-
degenerative diseases. In HD, we can identify people destined to get
the disease, but amajor challenge is measuringwhether a drug is work-
ing to prevent onset. By any established clinical measure, mutation car-
riers are indistinguishable from controls until they develop symptoms.
So, large cohorts of patients and mutation carriers were assembled
and studied over years, to determine what measurements were most
reliable for predicting onset and progression. The result was a toolkit
of imaging, clinical and cognitive biomarkers that can be used to facili-
tate clinical trials (Tabrizi et al., 2013). Last year, we reported the ﬁrst
quantiﬁcation of mutant huntingtin protein in cerebrospinal ﬂuid
(CSF), and showed that its concentration predicts clinical features of
HD. This is the smoking gun itself, released from the neurons it is killing
(Wild et al., 2015). We now need to enlist large cohorts of well-
characterised HDmutation carriers and study their CSF comprehensive-
ly: this is the aim of our nascent HDClarity study (http://hdclarity.net).
In September 2015, the ﬁrst dose of an antisense oligonucleotide
drug – a chemically-modiﬁed single DNA strand – was injected into
the CSF of a patient with HD (BBC News, 2015). The global trial, led by
our centre at UCL, is designed to test the safety of the drug, IONIS-
HTTRx, developed by Ionis Pharmaceuticals, aimed at suppressing pro-
duction of huntingtin in the human brain (ClinicalTrials.gov, 2015).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Somemilestones on the road to huntingtin-lowering investigational therapies for HDpatients. 1990, RNA interference is described after overexpression of pigmentation enzymes in
petunia ﬂowers (left) is seen to produce paradoxical reductions in pigment (right) due to co-suppression by interfering RNA. Modiﬁed fromMatzke and Matzke, 2004. 1993, the genetic
expansion in HTT responsible for HD is identiﬁed by a global collaborative research group (reproduced from The Huntington's Disease Collaborative Research Group, 1993 with
permission). 1996, Bates and colleagues report the ﬁrst transgenic mouse model of HD, the R6/2, still widely in use (reproduced from Mangiarini et al., 1996 with permission). 2005,
the ﬁrst report of oligonucleotide-based huntingtin suppression in a mouse model of HD resulting in improved motor function towards wild-type level. Red box shows transgenic
animals treated with active compound. (modiﬁed from Harper et al., 2005.) 2015 (middle row), ﬁrst successful quantiﬁcation of mutant huntingtin protein in cerebrospinal ﬂuid from
HD mutation carriers using a novel single-molecule counting immunoassay (modiﬁed fromWild et al., 2015 with permission.) 2015 (bottom row), the ﬁrst trial of an oligonucleotide
huntingtin-lowering compound, IONIS-HTTRx, begins in HD patients (screenshots from ClinicalTrials.gov and BBC News, 2015, edited for clarity).
4 E.J. Wild / EBioMedicine 8 (2016) 3–4Among other measures, huntingtin will be quantiﬁed in CSF to look for
evidence that the drug is engaging with its target.
This trial marks a huge step towards treatments to improve the sit-
uation of HD-affected families. It owes its existence to decades in paral-
lel pursuit of basic and clinical pathobiology, therapeutic development,
biomarker discovery, clinical trials and patient education (e.g. http://
hdbuzz.net). Testing the efﬁcacy of this ﬁrst huntingtin-lowering drug
alone will take several years, and of course there may be setbacks
ahead. It is to be hoped that whatever can be accomplished in HD will
illuminate the global ﬁght against neurodegenerative disease.
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